CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 509 enrolled
Drug / intervention
CT-P43 +1 morebiological
Likely dose
CT-P43 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04673786
NCT04673786Phase 3Completed
CompareCT.gov

A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Moderate to Severe Plaque Psoriasis

Celltrion·interventional·Posted Dec 17, 2020·Updated Jun 5, 2023

In Brief

A Phase 3 clinical trial evaluating CT-P43 and Stelara for Psoriasis. Completed, enrolled 509 participants across 1 site.

Detailed Summary

This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesEstonia
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedDec 17, 2020
Enrollment StartJan 11, 2021
Primary CompletionAug 4, 2021
Study CompletionMay 12, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.5 years ago

Interventions

CT-P43biological

45mg or 90mg dose subcutaneous administration

Stelarabiological

45mg or 90mg dose subcutaneous administration